Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
event icon
Introducing NaOH-stable AAV affinity resins: the first chapter of a growing catalog
The first and only NaOH-cleanable affinity resins for AAV2, AAV8 and AAV9 have been developed using a breakthrough development platform based on unprecedented ligand diversity. Performance metrics for capacity, yield and purity meet or exceed existing AAV resins while also withstanding more than 20 CIP cycles with 0.5 M NaOH. Off-the-shelf resin availability pre-packed in OPUS® Columns, as well as loose resin, enables streamlined implementation. The technical basis of the development platform and example data will be discussed.
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $271.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 10, 2020 subject to customary closing conditions.

Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 3, 2019 subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. These securities
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the pricing of an underwritten public offering of 2,807,017 shares of its common stock at a public offering price of $42.75 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 421,052  shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $120 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 3, 2017, subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott LLC is acting as lead co-manager for the offering and
store icon
IPA 300S Resin – Repligen
IPA 300S is a Repligen legacy Protein A affinity resin used in commercial manufacturing processes for therapeutic antibodies. This resin can also be used for bench-scale experiments and immunoprecipitation (IP) methods. IPA 300S incorporates Repligens srPA50 ligand immobiized onto an agarose bead.
event icon
Viral vector N-1 intensification reduces seed train vessel number, media volume and time
The demand for gene therapy viral vectors requires manufacturing processes to scale up to 2000 L. Viral vector production at this scale requires a 9- to 12-day seed train with two to three seeding bioreactors, increasing the risk of failure and manufacturing cost. Perfusion-based cell culture intensification techniques shorten and simplify the seed train for recombinant proteins and monoclonal antibodies production by reducing time, equipment, bioreactor size and cost while increasing the potential number of batches per year. This webinar will discuss similar efficiency gains for three different viral vectors (lentivirus, AAV8 and AAV9) through intensification using KrosFlo® TFDF® Technology that resulted in reduce train vessel number, N-1 vessel size, media volume and time.
news icon
Repligen Appoints Jacob Johnson As Vice President Investor Relations
event icon
Realization of PAT inline using variable pathlength spectroscopy - applications in downstream mAbs and viral vector purification
The first and only variable pathlength analysis technology has been integrated in-line with flow paths for PAT use in downstream unit operations. Rapid and accurate real-time results were acquired on the widest range of samples and concentrations (from less than 1 mg/mL to over 300 mg/mL), revealing previously unrecognized process characteristics.
store icon
Magnetic Weighted Tubing Closure – Repligen
Autoclavable Spectra/Por Magnetic-Weighted Closures contain a magnetic fluorocarbon coated stainless steel bar, eliminating the need for conventional stir bars. Applied to the bottom end of the dialysis tubing, this closure provides complete submersion and gentle rotation of the sample on a stir plate.
event icon
Turbocharging pDNA Production: CDMO Case Study in Optimization
Improvements in plasmid DNA manufacturing processes are a MUST to satisfy the rising demand driven by gene therapies. Watch this insightful case study where we delve into advancements in plasmid DNA production through optimizing Tangential Flow Filtration (TFF). Learn how Forge Biologics, in collaboration with Repligen, achieved a 300% reduction in processing time while enhancing RNA removal and maintaining high supercoiled DNA levels. Discover the impact of molecular weight cutoff and shear rate on plasmid DNA purification and strategies for successful scale-up to larger manufacturing environments. Uncover technologies and techniques designed to: Reduce processing time by ~300% Address suboptimal RNA and protein removal Streamline scale-up for large volume manufacturing Highlight the importance of advanced process controls
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support